We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Direct Effect Media/Illumina

PerkinElmer Acquires Indian IVD Firm Tulip Diagnostics

By Labmedica International staff writers
Posted on 17 Jan 2017
Print article
Image: PerkinElmer has entered into an agreement to acquire Tulip Diagnostics (Photo courtesy of iStock).
Image: PerkinElmer has entered into an agreement to acquire Tulip Diagnostics (Photo courtesy of iStock).
PerkinElmer, Inc., which offers products, services and solutions for the diagnostics, research, environmental, industrial and laboratory services market, has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd., one of India’s largest domestic providers of in-vitro diagnostic reagents, kits and instruments.

PerkinElmer offers a global diagnostics portfolio focused on: reproductive health, infectious disease screening and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings. The company also offers instruments and services to its customers in India where it even has a laboratory for providing access to technologies that screen for and help diagnose prenatal and neonatal conditions.

Tulip’s solutions include products for the prevention, screening and diagnosis of infectious diseases such as malaria, HIV and hepatitis, and it has two manufacturing facilities located in India.

“In-vitro diagnostics is one of the fastest growing vertical segments in India, and Tulip provides the key enablers for PerkinElmer to broaden our infectious disease screening menu and capabilities for customers throughout the region,” said Jayashree Thacker, President, PerkinElmer India. “The acquisition underscores our commitment to bringing advanced healthcare innovations into India, while continuing to further expand our footprint in the country.”

“Combining our product portfolio and channel access in India with PerkinElmer’s established position as a global diagnostics provider enables us to work closely with customers in India to bring the latest infectious disease technologies to them at an affordable cost,” said Deepak Tripathi, Director and Co-founder of Tulip.

Print article


Copyright © 2000-2018 Globetech Media. All rights reserved.